Join
Live feed
·
PRReleasevia Quantisnow
Bright Minds Biosciences Inc. logo

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

ByQuantisnow·Wall Street's wire, on your screen.
DRUG· Bright Minds Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DRUG (Bright Minds Biosciences Inc.) and more on Quantisnow.